XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.1
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
OPERATING EXPENSES        
Research and development $ 7,268,257 $ 4,618,436 $ 11,754,029 $ 7,205,584
Financing costs (Notes 7 and 8) 299 88,369 1,480 303,870
General and administration 4,615,332 4,863,608 6,824,249 7,002,773
Total operating expenses (11,883,888) (9,570,413) (18,579,758) (14,512,227)
Foreign exchange 7,649 (17,831) 14,845 (11,622)
Interest income 39,208 205,641 74,899 306,606
Derivative liability gain (loss) (Note 9) (1,128,216) 32,676 (1,039,086) (23,957)
Loss for the period before taxes (12,965,247) (9,349,927) (19,529,100) (14,241,200)
Income tax recovery 0 (4,000) 35,149 274,000
Loss and comprehensive loss for the period $ (12,965,247) $ (9,353,927) $ (19,493,951) $ (13,967,200)
Basic and diluted loss per common share $ (0.36) $ (0.45) $ (0.56) $ (0.67)
Weighted average number of common shares outstanding - basic and diluted 36,484,041 20,821,956 34,896,509 20,790,817